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Background: Rectal and pararectal gastrointestinal stromal tumors (GISTs) are rare. The optimal management
strategy for primary localized GISTs remains poorly defined.
Methods: We conducted a retrospective analysis of 41 patients with localized rectal or pararectal GISTs treated
between 1991 and 2011 in 13 French Sarcoma Group centers.
Results: Of 12 patients who received preoperative imatinib therapy for a median duration of 7 (2-12) months, 8
experienced a partial response, 3 had stable disease, and 1 had a complete response. Thirty and 11 patients
underwent function-sparing conservative surgery and abdominoperineal resection, respectively. Tumor resections
were mostly R0 and R1 in 35 patients. Tumor rupture occurred in 12 patients. Eleven patients received postoperative
imatinib with a median follow-up of 59 (2.4-186) months. The median time to disease relapse was 36 (9.8-62)
months. The 5-year overall survival rate was 86.5%. Twenty patients developed local recurrence after surgery alone,
two developed recurrence after resection combined with preoperative and/or postoperative imatinib, and eight
developed metastases. In univariate analysis, the mitotic index (≤5) and tumor size (≤5 cm) were associated with a
significantly decreased risk of local relapse. Perioperative imatinib was associated with a significantly reduced risk of
overall relapse and local relapse.
Conclusions: Perioperative imatinib therapy was associated with improved disease-free survival. Preoperative
imatinib was effective. Tumor shrinkage has a clear benefit for local excision in terms of feasibility and function
preservation. Given the complexity of rectal GISTs, referral of patients with this rare disease to expert centers to
undergo a multidisciplinary approach is recommended.Background
Gastrointestinal stromal tumors (GISTs) are rare but
nonetheless represent the most common mesenchymal
tumors of the gastrointestinal tract. The majority of GISTs
arise in the stomach and small intestine [1], with an esti-
mated annual incidence of 11 to 14.5 per million [2,3].* Correspondence: thanh-khoa.huynh@mail.ap-hm.fr
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reproduction in any medium, provided the orRectal/pararectal GISTs are very rare and represent only 3
to 5% of all GISTs. Their incidence is estimated at 0.45
per million per year [4]. Few series of rectal GISTs have
been reported in the literature, and the available reports
are limited to a small number of cases [5-7].
Due to the rarity of rectal GISTs and the limited number
of published studies, there is a paucity of data on how to
optimally handle rectal GISTs. There is a tendency to treat
rectal/pararectal GISTs as other GISTs, particularly as
gastric GISTs. Management typically involves en bloc re-
section of the tumor, which avoids tumor rupture andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tomy because lymphatic metastases are exceedingly rare.
Nevertheless, rectal/pararectal GISTs have a high risk of
recurrence (local recurrence or metastasis), ranging from
55% for tumors of >5 cm with a mitotic index (MI) of ≤5/
50 HPF to 85% for tumors with an MI of >5/50 HPF re-
gardless of size [8].
Surgery remains the only curative treatment for GISTs.
However, because of the specific location of rectal GISTs,
surgery is technically difficult and often extensive, possibly
involving abdominoperineal or multivisceral resections,
and raises the problem of sphincter preservation. Exten-
sive surgery may result in considerable functional morbid-
ity based on the tumor size, exact location of the tumor,
and relationship of the tumor with vital pelvic structures
(i.e., bladder, pelvic nerves, and anal sphincters). There-
fore, the ability to shrink such a tumor in a safe and reli-
able manner is crucial to facilitate the performance of
function-sparing surgical resection of disease.
Imatinib is a selective receptor tyrosine kinase inhibi-
tor of the KIT and PDGFR-α receptor tyrosine kinases,
which are pathophysiological drivers of GISTs. Imatinib
is approved worldwide as a first-line systemic treatment
for KIT-positive unresectable and/or metastatic GISTs
and has revolutionized their treatment [9]. Since 2005,
several case reports and small series regarding use of
preoperative “neoadjuvant” imatinib treatment for rectal
GISTs have been published [10-14], and some larger
series have been more recently published [15,16]. These
studies have shown that significant downstaging can be
achieved with this targeted therapy, thus allowing con-
servative surgical procedures to be performed. More re-
cently, imatinib treatment has been considered in the
adjuvant setting to lower the risk of relapse [17]. Pub-
lished reports of patients with rectal GISTs treated since
the approval of imatinib, which has dramatically chan-
ged the treatment options and prognosis for GISTs, are
rare [15,16].
We conducted a 19-year retrospective analysis of
rectal/pararectal GISTs with the aim of reviewing the
clinicopathological characteristics, diagnostic and treat-
ment approaches, choice of surgical procedure, peri-
operative use of imatinib, patterns of failure, and early
and long-term results including overall survival and
event-free survival.
Methods
We collected data of adult patients with rectal/pararectal
GISTs treated from November 1991 to March 2011 in
12 French Sarcoma Group institutions and the Centre
Hospitalier Universitaire Vaudois (CHUV) Lausanne. A
standard data file was created to retrieve information on
patient characteristics (gender, age at diagnosis, Eastern
Cooperative Oncology Group [ECOG] performancestatus, and initial clinical symptoms), clinicopathological
tumor characteristics, treatment approaches including
surgical management and medical treatment (neoadju-
vant and/or adjuvant imatinib), and patterns of failure
(local recurrence or distant metastasis). Follow-up infor-
mation was obtained during outpatient visits.
The diagnosis of GIST was confirmed by an experienced
local pathologist using morphology and immunohisto-
chemical staining for KIT (CD117) and CD34. Seven
GISTs diagnosed as leiomyosarcoma before the year 2000
were reclassified as GISTs at the time of recurrence.
Tumors were classified using standard risk assessment cri-
teria using both the classification proposed by Fletcher
(NIH consensus risk) [18], which is based on tumor size
and number of mitoses, and the classification proposed by
Miettinen [19], which is based on the MI, tumor size, and
tumor site.Ethics statement
This was a retrospective minimal-risk review, and all
patients consented to the use of their standard clinical
data. Our institutional review board exempts such
minimal-risk survey studies from requiring institutional
review board approval according to French laws. The
board of directors of the French Sarcoma Group ap-
proved the study.Statistical analysis
Continuous variables are expressed as median (range),
and categorical variables are expressed as percentages.
We retrospectively analyzed all prognostic factors, in-
cluding patient characteristics (sex, age, ECOG per-
formance status), tumor characteristics (tumor site in
rectum, tumor size, KIT, CD34, MI/50 HPF, NIH cat-
egories, Miettinen categories, necrosis, histological sub-
type, and mutational status), surgical management (type
of procedure, radical vs conservative surgery, margins
[R0 vs R1 vs R2 or R0 vs R1-R2 or R0-R1 vs R2], tumor
rupture, surgery-related complications), and medical
treatment (imatinib treatment group vs non-imatinib
treatment group). Fisher’s exact test was used to com-
pare percentages. Survival curves were plotted using the
Kaplan–Meier method and compared with the log-rank
test. Overall survival was calculated based on the inter-
val from diagnosis to patient’s death or last follow-up.
Local relapse-free survival was defined as the interval
between diagnosis and any subsequent occurrence of a
tumor in the same location. Event-free survival was de-
fined as the interval between diagnosis and local relapse
and/or distant metastasis. All statistical tests were two-
sided, and the threshold for statistical significance was
set at p = 0.05. Analyses were performed with SPSS soft-
ware, version 17.0 (SPSS Inc., IL, USA).
Huynh et al. BMC Cancer 2014, 14:156 Page 3 of 9
http://www.biomedcentral.com/1471-2407/14/156Results
Patient and disease characteristics
Patient and tumor characteristics are described in Table 1.
During the period from November 1991 to March
2011, a total of 41 adult patients with localized rectal/
pararectal GISTs were included in this review, including
4 patients reported in a separate therapeutic trial known
as the French Sarcoma Group BFR 14 study [20]. The me-
dian age at diagnosis was 60 years (range, 33-82 years).
The staging of the primary tumor included abdominopelvic
computed tomography (CT) in 21 patients (51%), pelvic
magnetic resonance imaging (MRI) in 18 patients (44%),
endorectal ultrasonography in 23 patients (56%), and posi-
tron emission tomography–CT in 6 patients (15%).
The median tumor size was 62 mm (range, 6-130 mm).
GISTs were mostly located in the middle third (9 patients,
24%) and lower third (22 patients, 50%) of the rectum.
Only seven GISTs (17%) were located in pararectal spaces
(presacral space, ischiorectal fossa, rectovaginal space, and
rectoprostatic space). Histologically, the tumors were pre-
dominantly spindle-cell type (n = 31, 76%). Immunohisto-
chemically, 83% of the tumors were KIT (CD117)-positive,
and 78% were CD34-positive. The mutational status was
determined in only 12 cases and revealed KIT exon 11
mutations in 10 cases.
Treatment
Treatment modalities (surgery and imatinib therapy) are
presented in Table 2.
Treatment strategy
All patients underwent tumor resection. Twenty-five pa-
tients underwent surgery only. Imatinib was not given
either because of the small tumor size or because it was
not available at the time of diagnosis. A total of 16 pa-
tients underwent operations and received preoperative
(n = 5), postoperative (n = 4), or preoperative and postop-
erative (n = 7) receptor tyrosine kinase inhibitor therapy
with imatinib. Twenty-nine (70%) patients underwent sur-
gery as the initial treatment, but 12 were treated with ima-
tinib preoperatively because of the tumor size.
Surgery
All patients underwent surgery. Different types of surgi-
cal procedures were performed. Local removal of the
tumor was performed in 30 of 41 patients and involved
anterior resection with coloanal or sus-anal anastomosis
in 12 (29%) patients, transanal/trans-sacral/transvaginal
resection in 7 (17%) patients, endoanal/endovaginal exci-
sion in 6 (14.6%) patients, and unspecified resection in 5
(12%) patients, resulting in 14 R0, 10 R1, and 4 R2 resec-
tions of 30 conservative surgeries and 2 unspecified re-
sections. Abdominoperineal resection was performed in
11 of 41 (27%) patients, resulting in 8 of 11 R0, 3 of 11R1, and no R2 resections. In proportion, sphincter-sparing
surgery was performed in 61% of patients, and abdomino-
perineal resection was performed in 27% of patients.
Abdominoperineal resection was more likely to result in
negative margins than local surgery (8 of 11 vs 14 of 30,
respectively; p < 0.05).
Seven patients (17%) experienced complications re-
lated to surgery: infection (n = 4), occlusion (n = 1), and
disunity of the coloanal anastomosis (n = 2). Complica-
tions were fatal in one patient who died of a small bowel
fistula. Tumor rupture occurred during surgery in nine
patients (22%).
Preoperative imatinib therapy
Among the 41 patients, 12 (30%) received preoperative
imatinib at 400 mg daily before surgical resection, with a
median preoperative treatment period of 7 months
(range, 2-12 months). All tumors except two were in the
inferior third of the rectum. The tumor response was
assessed every 2 to 3 months by CT and/or MRI. Of the
12 patients, 8 showed a partial response according to
Response Evaluation Criteria in Solid Tumors (RECIST),
1 had a complete response, and 3 had stable disease or a
minor response.
Two patients underwent abdominoperineal resection
despite a partial response after imatinib therapy; all had
negative margins and no postoperative complications.
Ten patients underwent a sphincter-sparing surgery; all
except one had negative margins (R0), and four of them
had postoperative complications.
Postoperative imatinib therapy
According to their estimated risk of relapse, 11 (27%)
patients were treated with imatinib postoperatively at
400 mg/day for a median duration of 7 months (range,
2-41 months). Seven after surgery performed after pre-
operative imatinib therapy and four after surgery only.
Patient outcomes (Table 3)
Recurrence
Local recurrence occurred in 20 (49%) patients, includ-
ing 18 (72%) in the non-imatinib treatment group and
only 2 (16%) in the imatinib treatment group (p < 0.001).
The median follow-up duration in the imatinib treat-
ment group was 39 months (range, 5-81 months), and
that in the non-imatinib treatment group was 68 months
(range, 2-186 months).
Among the 20 local recurrences, 6 (54.6%) developed
in the 11 patients who underwent abdominoperineal re-
section (exclusively in the non-imatinib treatment group),
and 14 (46%) developed among the 30 patients who
underwent local resection (2 who received imatinib and
12 who did not receive imatinib). Furthermore, these local
recurrences developed in 8 of 22 patients after R0
Table 1 Patient and tumor characteristics
Characteristics n = 41
Gender
Male 29 (71%)
Female 12 (29%)
Age (years)
Median (min-max) 60 (33-82)
ECOG
0/1 16/15 (98%)
Symptoms-Clinical manifestations
Abdominal pain 9 (22%)
Constipation 4 (10%)
Rectal bleeding 5 (12%)
Accidental discovery 9 (22%)
Others (genito urinary, pelvic
heaviness)
6 (15%)
Unknown 8 (19%)
Tumor characteristics
Tumor location
Rectum (Middle third/Lower third) 9/22 (24/50%)
Pararectal space 7 (17%)
Unspecified 3 (9%)
Tumor size (mm)
median (min-max) 62 (6-130)
Evaluated by:
Abdominopelvic CT Scan 21 (51%)
MRI 18 (44%)
Endosonography 23 (56%)
Unknown 6 (14%)
Histology/Genotype/risk
CD117+ 34 (83%)
CD34+
Mitotic index
≤ 5/50 HPF 11 (27%)
> 5/50 HPF 21 (51%)
Unknown 9 (22%)
Mutation status (done on 12 cases) KIT Exon 11 mutation in 10/12
KIT Exon 9 mutation in 1/12
KIT Exon 17 mutation in 1/12
None PDGFRA mutation
NIH risk categories
Very low risk 3 (7%)
Low risk 3 (7%)
Intermediate risk 6 (14%)
High risk 18 (42%)
Table 1 Patient and tumor characteristics (Continued)
Miettinen risk categories
None risk 3 (7%)
Low risk 4 (10%)
High risk 23 (56%)
Insufficient data (unclassified) 11 (26%)
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patients after R2 resection. Eight of 41 patients (20%) de-
veloped distant metastases: 6 (24%) in the non-imatinib
treatment group and 2 (13%) in the imatinib treatment
group (p = 0.448).
Survival analysis and prognostic factors
The median overall follow-up period was 59 months
(range, 2.4-186 months). Nine patients died during the
follow-up period. The 3-and 5-year overall survival rates
of patients with localized rectal/pararectal GISTs were
97.5 and 86.5%, respectively (Figure 1A). The median
event-free survival period was 36 months (range, 9.8-
62 months), with 3-and 5-year event-free survival rates
of 53.9 and 34.6%, respectively (Figure 1B). The median
local relapse-free survival period was 58 months (range,
29-86 months), with 3-and 5-year local relapse-free sur-
vival rates of 60.2 and 42.1%, respectively (Figure 1C).
In the univariate analysis, only tumor size (p = 0.004)
(Figure 2A), mitotic count (p = 0.048) (Figure 2B), NIH
risk (p = 0.023) (Figure 2C), and imatinib treatment (p =
0.006) (Figure 2D) were predictive of local relapse.
A tumor size of larger than 5 cm and an MI of higher
than 5/50 HPF increased the risk of local recurrence, as
expected with these known prognostic factors [16]. A
low MI (≤5/50 HPF) (p = 0.008) and imatinib treatment
(p = 0.011) were associated with a significantly lower risk
of overall relapse (local recurrence and distant metasta-
sis), but had no impact on overall survival. Sex, age, NIH
risk, Miettinen risk categories, tumor margins, tumor
rupture, and tumor local control had no influence on
event-free survival or overall survival in the univariate
analysis. In the multivariate analysis, we could not dem-
onstrate whether tumor size, MI, or NIH risk were inde-
pendent factors.
Preoperative and/or postoperative imatinib treatment
significantly reduced the risk of overall relapse (p = 0.011)
and local relapse (p = 0.006) (Figure 2D), with a significant
impact on disease-free survival but no demonstrable im-
pact on overall survival.
Discussion
GISTs are unusual tumors overall, while rectal GISTs are
a particularly rare subtype, representing less than 5% of
all GISTs. Few data are available on the presentation,
Table 2 Results of treatment
Characteristic n = 41 localized
tumors
Quality of surgery
Resection
R0 22 (53%)
R1 13 (32%)
R2 4 (10%)
Tumor rupture
Yes 9 (22%)
No 29 (70%)
Primary surgery/Post imatinib surgery 29/12
Post-operative complications 7 (17%)
Anastomotic leakage of coloanal anastomosis 2
Small bowel fistula with death 1
Pelvic peritonitis 1
Pararectal abscess and anorectal fistula 1
Occlusion 1
Fever 1
Imatinib (IM) therapy group (400 mg/day) 16 (37.5%)
Preoperative IM 12 (30%)
No neoadjuvant IM group (immediate surgery) 29 (70%)
Post operative IM 11 (27%)
from « neoadjuvant group » 7
from « immediate surgery group » 4
Median duration preoperative IM (month) 7 (2-12)
Median duration post operative IM (month) 7 (2-41)
Efficacy of preoperative IM therapy 12
Partial response 8
Complete response 1
Stable disease/minor response 3
Table 3 Outcome
Characteristics n = 41 localized
tumors
Follow-up (month)
Median 59
min 2.4
max 186
Prognosis
Death 9
Local relapse 20 (49%)
Metastases 8
Local relapse
In the « non imatinib treatment group » 18 (72%)
In the « imatinib treatment group » 2 (16%)
6/11 patients (54.5%) who underwent
abdominoperineal resection (exclusively
in « non IM group)
Metastases
In the « non imatinib treatment group » 6
In the « imatinib treatment group » 2
Local relapse-free survival at 3 years 60.2% [CI95% = 45.8-79.1]
Local relapse-free survival at 5 years 42.1% [CI95% = 26.8-66.3]
DFS at 3 years 53.9% [CI95% = 39.3-73.8%]
DFS at 5 years 34.6% [CI95% = 19.9-60.2%]
OS at 3 years 97.5% [CI95% = 92.8-100%]
OS at 5 years 86.5% [CI95% = 74.9-100%]
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tal GISTs.
Our retrospective study of 41 localized rectal GISTs over
the last 20 years is, to our knowledge, one of the largest
series currently reported in the literature. The two most
recent and large series on primary rectal GISTs reported
39 cases from 2 referral departments for sarcomas/GIST
surgeries over the last 8 years [16] and 32 cases from 6
surgical oncology and medical oncology departments in
the Netherlands over the last 21 years [15].
Patient demographics showed a male predominance
(71%), as already suggested in other series on primary
rectal GISTs [8,15,16,21], although most large epidemio-
logical studies of GISTs overall have shown a well-balanced
sex ratio with respect to incidence [2,22]. The presentation
and symptoms of these 41 rectal GISTs were not differentfrom those commonly found for other rectal tumors des-
pite the fact that the clinical presentation was sometimes
misleading, with rectal GISTs causing genitourinary and
gynecological symptoms because of compression or inva-
sion of adjacent pelvic organs. Therefore, we agree with
other authors [6,16,23] that pelvic/rectal GISTs should be
integrated into the framework of differential diagnoses
along with other submucosal rectal and pelvic tumors.
The mutational status was only determined in a subset
of 12 patients, in whom KIT exon 11 mutations were
demonstrated in 10, KIT exon 9 mutation in 1, and no
mutation in 1. In this retrospective study, tumor muta-
tional testing for the oncogenic KIT and/or PDGFRA
genes was able to be performed in only 12 of 41 (29%)
of these rare patients with rectal GISTs. Given the known
challenges described below, obtaining evaluable tissues
from patients identified over more than a decade is simply
not feasible. In three patients who underwent resection of
the primary tumor between 2000 and 2008, paraffin-
embedded blocks were collected, but the quality of tumor
material was insufficient to perform mutational testing be-
cause of technical challenges associated with these older
blocks and the tissue fixation procedure. For nine other
A: Overall survival B: Disease-free survival C: Local relapse-free survival
Figure 1 Survival curves.
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1999, and the quality of the tissue specimen from the
primary tumor was insufficient to determine the muta-
tional status. Thus, despite our best efforts, retrospect-
ive mutational examination of any additional patients inFigure 2 Factor associated with local relapsed-free survival.our series is unfortunately not possible. However, our
team believes that the information provided in this
series is useful because tumor mutational testing is
routinely performed in only a minority (approximately
5%) of GISTs worldwide. Nevertheless, the mutation
Huynh et al. BMC Cancer 2014, 14:156 Page 7 of 9
http://www.biomedcentral.com/1471-2407/14/156frequency in rectal GISTs has not been specifically in-
vestigated [15,16] except in Miettinen’s study [8], which
found mutations in 18 of 29 (62%) of the cases evalu-
ated, with a predominance of KIT exon 11 mutations, a
lack of KIT exon 13 mutations, and only one KIT exon
9 mutation.
In our study, 56% of the patients were classified in the
high-risk group according to the Miettinen classification
[19], and 56% of patients relapsed after surgical resection
of primary localized GISTs with disease-free survival
rates of 53.9 and 34.6% at 3 and 5 years, respectively.
This confirms the more aggressive behavior of rectal
GISTs. These data also corroborated the results of Mussi
et al. [21], Tsai et al. [24], and Miettinen et al. [8], who
showed that the majority of rectal GISTs are large,
demonstrate high-risk malignant behavior, and have a
tendency to recur and metastasize. Furthermore, in three
Korean studies, colorectal GISTs occurred predomin-
antly in the rectum and tended to be classified as
high-risk, which was the most important risk factor for
recurrence [25-27].
The cornerstone in treatment for patients with local-
ized GISTs is complete surgical resection with en bloc
tumor removal and clear margins, avoiding tumor rup-
ture. In our series, the relatively high rate of tumor rup-
ture during surgical resection might be explained by
several factors in this rare subset of patients with GIST.
In particular, this is a particularly challenging anatomical
location for primary GISTs, and the risk of rupture def-
initely seems higher than that in many other sites. In
five of our patients, the large size of the primary tumor
(8–10 cm) in this constrained anatomic space likely
contributed to the risk of rupture. In another three pa-
tients, the surgical resection was performed by endoanal
or transvaginal enucleation with resultant fragmentation
of the tumor. Conversely, rectal GISTs are often large
tumors. Therefore, they are a challenge for surgeons be-
cause of the confined pelvic space (anatomical location
close to the anal sphincters, pelvic nerves, and bladder)
and the fact that they are often adherent to the pelvic
floor. As a consequence, rectal GISTs might require
extensive surgery (e.g., abdominoperineal or multivisc-
eral resection) to achieve complete surgical resection.
Nevertheless, various conservative surgical procedures
and approaches may be considered for rectal GISTs,
including local excision, anterior resection, trans-sacral/
anal/vaginal approaches, and laparoscopic approaches
[28-30]. The choice of the procedure mainly depends on
the tumor size and location in relation to the anorectal
margin. In our series, only 11 (27%) patients underwent
abdominoperineal resection, and 30 patients were eligible
for conservative surgery with various surgical procedures.
Nevertheless, resections with clear margins (R0 resec-
tions) were more common with abdominoperinealprocedures than with conservative surgery (8/11 and 14/
30, respectively), but tumor recurrence occurred simi-
larly in both groups of patients: in 6 of 11 patients (54%)
after abdominoperineal surgery and in 11 of 30 patients
(46.6%) after conservative surgery.
Because of the rarity of this disease, no prospective stud-
ies have compared radical surgery versus conservative sur-
gery or local tumor excision, and only such a study could
elucidate the value of this radical surgery. Khalifa et al.
[31] reported that there was no difference in survival rates
between local resection and abdominoperineal resection
in patients with rectal sarcoma. We believe that local re-
section should be performed if microscopically clear mar-
gins can be safely achieved.
Preoperative imatinib therapy was administered to 12
(30%) of the patients in this series because of large GISTs,
difficulty of complete tumor removal, and preservation of
the anal sphincters. In all cases, it enabled a modification
in tumor size and/or density. It also permitted the per-
formance of conservative surgery in 8 of 12 patients (6 of
these 8 tumors were located in the lower third of the rec-
tum). Thus, this treatment was feasible, safe, and effective.
Since 2005, several case reports or small series regarding
the use of preoperative imatinib treatment for rectal
GISTs have been published [10-13,32-35]. All concluded
that preoperative imatinib therapy has an important role
in downsizing large rectal GISTs and in reducing the mi-
totic activity. Because these tumors are in the vicinity of
pelvic structures (i.e., bladder, major pelvic nerves, and
anal sphincters) and given that radical surgery may lead to
considerable morbidity, downstaging might be beneficial
in this situation, allowing function-sparing procedures and
less invasive surgery while potentially improving tumor re-
sectability. Preoperative treatment is thus a reasonable op-
tion for patients with locally advanced rectal GISTs that
require abdominoperineal or multivisceral resection for
complete tumor removal.
Controversy remains regarding the optimal duration
of preoperative therapy. Our patients received preopera-
tive imatinib for a median duration of 7 months (range,
2–10 months). In the EORTC phase III trial, the median
time to best response was 4 months, but some responses
were documented later [36]. Similar observations have
been made in case reports of preoperative imatinib in lo-
calized diseases [37]. Therefore, it would be reasonable to
plan a final surgery within 6 to 12 months of imatinib
onset [34].
Interestingly in our series, 18 patients (72%) in the non-
imatinib group and only 2 (16%) in the imatinib group de-
veloped local recurrence. We showed that preoperative
and/or postoperative imatinib significantly reduced the
risk of not only local recurrence (p = 0.006), but also
overall relapse (p = 0.011), and significantly improved
the disease-free survival with no impact on overall
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from Andtbacka et al. [38] on 16 locally advanced GISTs
from several locations treated with preoperative imatinib
and those from Tielen et al. on 32 rectal GISTs, 22 treated
with preoperative imatinib and 10 with surgery only [15].
Conclusions
Based on these data, we suggest that a therapeutic strat-
egy combining surgery with preoperative imatinib ther-
apy should be systematically considered for patients with
rectal GISTs, specifically for patients with larger tumors,
marginally resectable tumors, or tumors close to the anal
sphincters because imatinib may potentially increase the
proportion of patients able to undergo conservative sur-
gery rather than the more morbid abdominoperineal
resection. Furthermore, according to the results of the
ACOSOG Z9001 study and two recent Scandinavian stud-
ies [17,39], the indication to continue imatinib in the post-
operative setting for a duration of at least 1 year has been
established in patients with high-risk GISTs, when incom-
plete surgical resection has occurred, or when tumor rup-
ture has occurred. This should be systematically discussed
with patients according to the risk of disease recurrence
per the standard risk assessment criteria.
Due to the rarity of these tumors, these decisions re-
quire the multidisciplinary expertise of surgeons, med-
ical oncologists, radiologists, and gastroenterologists in
expert centers. Referral of patients with this rare disease
to expert centers is recommended.
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